Browse studies

Find your next paid study

172 recruiting studies matching your filters

Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

This is a randomized, two-cohort, open-label, phase 3, clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (cohort A) or…

NSCLC Stage IV

Estimated

~$50 – $2,100

Actual pay is set by the research site.

ImmunityBio, Inc.NCT06745908

Phase 2

A Multi-center Phase II Study of Combining Cabozantinib and Atezolizumab as the 1st Line Therapy for PD-L1 Negative Advanced/Metastatic NSCLC (Cabatezo-1)

NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzu…

Lung CancerNSCLC Stage IVMetastatic NSCLC - Non-Small Cell Lung Cancer+1 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Jun Zhang, MD, PhDNCT05859217

Phase 1

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerabilit…

Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more

Estimated

~$150 – $4,500

Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC (TUMORIN)

To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving…

Lung CancerNSCLCNSCLC Stage IV

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Jun Zhang, MD, PhDNCT05332925

Phase 1

DURABLE: Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and rEarrangements

This study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28…

Lung CancerNSCLCBrain Metastases

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Joshua PalmerNCT05987644

Phase 1

Evaluation of the Distribution of CM500 in Healthy Volunteers and Patients With Cancer

The objective of this study is to assess two novel positron emission tomography (PET) radiotracers, \[64Cu\]CM500 and \[68Ga\]CM500, for Positron Emission Tomo…

Bladder CancerGliomaGlioblastoma (GBM)+13 more

Estimated

~$500 – $10,500

Actual pay is set by the research site.

Lumina Pharmaceuticals IncNCT07781852

Observational

Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer

This is a prospective pilot study to assess dynamic changes of plasma cell-free RNA (cfRNA) PD-L1 expression in patients with lung cancer undergoing immune che…

Lung Cancer (NSCLC)

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Ballad HealthNCT06849518

Observational

Rapid Onsite Cytopathologic Evaluation for Improved Molecular Marker Testing Via Endobronchial Ultrasound Bronchoscopy - A Randomized Controlled Trial

This research study is being done to compare two ways to conduct bronchoscopic biopsy of lymph nodes and other structures in the chest (i.e. the presence or ab…

Non-small Cell Lung Cancer (NSCLC)

Estimated

~$10 – $750

Actual pay is set by the research site.

Johns Hopkins UniversityNCT04945317

Phase 1

Phase 1/2 Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in c…

NSCLCHNSCCMelanoma+3 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

CJ Bioscience, Inc.NCT05877430

Phase 3

RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung CancerNSCLC+2 more

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Revolution Medicines, Inc.NCT06881784

Observational

Combining 4D MRI and 4DCT for Personalized Volumetric Motion Monitoring in Lung Radiation Therapy

The purpose of this study is to assess a real time motion tracking of lung tumors and important organs next to the tumor while breathing during a participant's…

Lung Cancer (NSCLC)Radiation

Estimated

~$10 – $750

Actual pay is set by the research site.

University of Maryland, BaltimoreNCT07398209

Phase 1

A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors

The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants w…

Head and Neck Squamous Cell Carcinoma (HNSCC)Pancreatic AdenocarcinomaNon-small Cell Lung Cancer (NSCLC)+3 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.